Do analysts prefer CGC or VRCA?

Verrica Pharmaceuticals has a consensus target price of $14.50, suggesting a potential upside of 111.99%. Given Verrica Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Verrica Pharmaceuticals is more favorable than Canopy Growth. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Canopy Growth 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 Verrica Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Does the media prefer CGC or VRCA?

In the previous week, Canopy Growth had 8 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 12 mentions for Canopy Growth and 4 mentions for Verrica Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 0.97 beat Canopy Growth's score of 0.48 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Canopy Growth 4 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Verrica Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor VRCA or SOPH?

In the previous week, SOPHiA GENETICS had 9 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 13 mentions for SOPHiA GENETICS and 4 mentions for Verrica Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 0.97 beat SOPHiA GENETICS's score of 0.27 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verrica Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SOPHiA GENETICS 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to LRMR or VRCA?

In the previous week, Verrica Pharmaceuticals had 1 more articles in the media than Larimar Therapeutics. MarketBeat recorded 4 mentions for Verrica Pharmaceuticals and 3 mentions for Larimar Therapeutics. Verrica Pharmaceuticals' average media sentiment score of 0.97 beat Larimar Therapeutics' score of 0.63 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Larimar Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verrica Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VRCA or CMPX?

In the previous week, Compass Therapeutics had 1 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 5 mentions for Compass Therapeutics and 4 mentions for Verrica Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 0.97 beat Compass Therapeutics' score of 0.60 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verrica Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Compass Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor VRCA or RCKT?

In the previous week, Verrica Pharmaceuticals had 1 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 4 mentions for Verrica Pharmaceuticals and 3 mentions for Rocket Pharmaceuticals. Rocket Pharmaceuticals' average media sentiment score of 1.22 beat Verrica Pharmaceuticals' score of 0.97 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verrica Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rocket Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Verrica Pharmaceuticals (VRCA) Competitors

$6.84 0.00 (0.00%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$4.84 -2.00 (-29.17%)

As of 05:30 AM Eastern

Compare

VRCA vs. CGC, SOPH, LRMR, CMPX, and RCKT

Should you buy Verrica Pharmaceuticals stock or one of its competitors? MarketBeat compares Verrica Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Verrica Pharmaceuticals include Canopy Growth (CGC), SOPHiA GENETICS (SOPH), Larimar Therapeutics (LRMR), Compass Therapeutics (CMPX), and Rocket Pharmaceuticals (RCKT). These companies are all part of the "pharmaceutical products" industry.

How does Verrica Pharmaceuticals compare to Canopy Growth?

Canopy Growth (NASDAQ:CGC) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

In the previous week, Canopy Growth had 8 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 12 mentions for Canopy Growth and 4 mentions for Verrica Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 0.97 beat Canopy Growth's score of 0.48 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Canopy Growth	4 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Verrica Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Canopy Growth has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market.

Verrica Pharmaceuticals has a net margin of -47.97% compared to Canopy Growth's net margin of -75.27%. Canopy Growth's return on equity of -26.95% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Canopy Growth	-75.27%	-26.95%	-17.20%
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%

Verrica Pharmaceuticals has a consensus target price of $14.50, suggesting a potential upside of 111.99%. Given Verrica Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Verrica Pharmaceuticals is more favorable than Canopy Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Canopy Growth	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

3.3% of Canopy Growth shares are owned by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. 0.2% of Canopy Growth shares are owned by company insiders. Comparatively, 54.0% of Verrica Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Verrica Pharmaceuticals has lower revenue, but higher earnings than Canopy Growth. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Canopy Growth	$251.01M	1.67	-$190.29M	-$0.59	N/A
Verrica Pharmaceuticals	$35.58M	3.30	-$17.89M	-$1.03	N/A

Summary

Verrica Pharmaceuticals beats Canopy Growth on 9 of the 15 factors compared between the two stocks.

How does Verrica Pharmaceuticals compare to SOPHiA GENETICS?

Verrica Pharmaceuticals (NASDAQ:VRCA) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Verrica Pharmaceuticals has higher earnings, but lower revenue than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Verrica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	3.30	-$17.89M	-$1.03	N/A
SOPHiA GENETICS	$77.27M	6.24	-$79M	-$0.52	N/A

In the previous week, SOPHiA GENETICS had 9 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 13 mentions for SOPHiA GENETICS and 4 mentions for Verrica Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 0.97 beat SOPHiA GENETICS's score of 0.27 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verrica Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SOPHiA GENETICS	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

SOPHiA GENETICS has a net margin of -44.48% compared to Verrica Pharmaceuticals' net margin of -47.97%. SOPHiA GENETICS's return on equity of -62.74% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%
SOPHiA GENETICS	-44.48%	-62.74%	-21.85%

Verrica Pharmaceuticals presently has a consensus price target of $14.50, suggesting a potential upside of 111.99%. SOPHiA GENETICS has a consensus price target of $7.50, suggesting a potential upside of 30.43%. Given Verrica Pharmaceuticals' higher probable upside, research analysts plainly believe Verrica Pharmaceuticals is more favorable than SOPHiA GENETICS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
SOPHiA GENETICS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are held by institutional investors. 54.0% of Verrica Pharmaceuticals shares are held by insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Verrica Pharmaceuticals has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market. Comparatively, SOPHiA GENETICS has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market.

Summary

SOPHiA GENETICS beats Verrica Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Verrica Pharmaceuticals compare to Larimar Therapeutics?

Larimar Therapeutics (NASDAQ:LRMR) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings.

In the previous week, Verrica Pharmaceuticals had 1 more articles in the media than Larimar Therapeutics. MarketBeat recorded 4 mentions for Verrica Pharmaceuticals and 3 mentions for Larimar Therapeutics. Verrica Pharmaceuticals' average media sentiment score of 0.97 beat Larimar Therapeutics' score of 0.63 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Larimar Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Verrica Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Larimar Therapeutics currently has a consensus price target of $13.50, suggesting a potential upside of 268.85%. Verrica Pharmaceuticals has a consensus price target of $14.50, suggesting a potential upside of 111.99%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Larimar Therapeutics is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Larimar Therapeutics has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market.

91.9% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. 4.5% of Larimar Therapeutics shares are owned by company insiders. Comparatively, 54.0% of Verrica Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Larimar Therapeutics has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -47.97%. Larimar Therapeutics' return on equity of -134.14% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-134.14%	-96.00%
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%

Verrica Pharmaceuticals has higher revenue and earnings than Larimar Therapeutics. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A
Verrica Pharmaceuticals	$35.58M	3.30	-$17.89M	-$1.03	N/A

Summary

Larimar Therapeutics and Verrica Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Verrica Pharmaceuticals compare to Compass Therapeutics?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

Verrica Pharmaceuticals currently has a consensus target price of $14.50, indicating a potential upside of 111.99%. Compass Therapeutics has a consensus target price of $12.91, indicating a potential upside of 520.63%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Compass Therapeutics is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Verrica Pharmaceuticals has higher revenue and earnings than Compass Therapeutics. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	3.30	-$17.89M	-$1.03	N/A
Compass Therapeutics	$850K	440.69	-$66.49M	-$0.41	N/A

In the previous week, Compass Therapeutics had 1 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 5 mentions for Compass Therapeutics and 4 mentions for Verrica Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 0.97 beat Compass Therapeutics' score of 0.60 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verrica Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Compass Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are owned by institutional investors. 54.0% of Verrica Pharmaceuticals shares are owned by company insiders. Comparatively, 18.7% of Compass Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Verrica Pharmaceuticals has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market. Comparatively, Compass Therapeutics has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market.

Compass Therapeutics has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -47.97%. Compass Therapeutics' return on equity of -39.75% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%
Compass Therapeutics	N/A	-39.75%	-35.29%

Summary

Compass Therapeutics beats Verrica Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Verrica Pharmaceuticals compare to Rocket Pharmaceuticals?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 54.0% of Verrica Pharmaceuticals shares are held by insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Verrica Pharmaceuticals had 1 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 4 mentions for Verrica Pharmaceuticals and 3 mentions for Rocket Pharmaceuticals. Rocket Pharmaceuticals' average media sentiment score of 1.22 beat Verrica Pharmaceuticals' score of 0.97 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verrica Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rocket Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Verrica Pharmaceuticals has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market. Comparatively, Rocket Pharmaceuticals has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market.

Verrica Pharmaceuticals has higher revenue and earnings than Rocket Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	3.30	-$17.89M	-$1.03	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$1.87	N/A

Rocket Pharmaceuticals has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -47.97%. Rocket Pharmaceuticals' return on equity of -69.61% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%
Rocket Pharmaceuticals	N/A	-69.61%	-58.63%

Verrica Pharmaceuticals currently has a consensus price target of $14.50, indicating a potential upside of 111.99%. Rocket Pharmaceuticals has a consensus price target of $8.88, indicating a potential upside of 173.08%. Given Rocket Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Rocket Pharmaceuticals	3 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.33

Summary

Rocket Pharmaceuticals beats Verrica Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Verrica Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRCA vs. The Competition

Export

Metric	Verrica Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$117.51M	$3.02B	$6.83B	$12.17B
Dividend Yield	N/A	1.88%	2.66%	6.11%
P/E Ratio	-6.64	19.54	25.89	24.17
Price / Sales	3.30	330.40	547.76	101.00
Price / Cash	N/A	56.85	29.09	36.93
Price / Book	4.41	4.21	10.75	6.38
Net Income	-$17.89M	$64.45M	$3.58B	$337.00M
7 Day Performance	21.28%	1.32%	1.97%	-0.20%
1 Month Performance	18.75%	-1.07%	-0.24%	-1.40%
1 Year Performance	30.88%	29.70%	34.39%	27.76%

Verrica Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRCA Verrica Pharmaceuticals	3.4461 of 5 stars	$6.84 flat	$14.50 +112.0%	+30.9%	$117.51M	$35.58M	N/A	40	Gap Down High Trading Volume
CGC Canopy Growth	1.1663 of 5 stars	$0.96 -1.0%	N/A	-23.4%	$386.78M	$251.01M	N/A	3,150	Gap Down
SOPH SOPHiA GENETICS	3.2584 of 5 stars	$5.34 -2.2%	$7.50 +40.4%	+86.1%	$383.36M	$77.27M	N/A	520	News Coverage Gap Down High Trading Volume
LRMR Larimar Therapeutics	2.4487 of 5 stars	$3.66 +0.5%	$15.29 +317.6%	+20.8%	$380.20M	N/A	N/A	30	Gap Down
CMPX Compass Therapeutics	3.5254 of 5 stars	$2.10 +4.0%	$12.91 +514.7%	-18.8%	$378.19M	$850K	N/A	20	News Coverage Negative News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VRCA) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Verrica Pharmaceuticals (VRCA) Competitors

VRCA vs. CGC, SOPH, LRMR, CMPX, and RCKT

How does Verrica Pharmaceuticals compare to Canopy Growth?

Summary

How does Verrica Pharmaceuticals compare to SOPHiA GENETICS?

Summary

How does Verrica Pharmaceuticals compare to Larimar Therapeutics?

Summary

How does Verrica Pharmaceuticals compare to Compass Therapeutics?

Summary

How does Verrica Pharmaceuticals compare to Rocket Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRCA vs. The Competition

Verrica Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Verrica Pharmaceuticals (VRCA) Competitors

VRCA vs. CGC, SOPH, LRMR, CMPX, and RCKT

How does Verrica Pharmaceuticals compare to Canopy Growth?

Does the media prefer CGC or VRCA?

Which has more risk and volatility, CGC or VRCA?

Is CGC or VRCA more profitable?

Do analysts prefer CGC or VRCA?

Do institutionals & insiders have more ownership in CGC or VRCA?

Which has higher earnings & valuation, CGC or VRCA?

Summary

How does Verrica Pharmaceuticals compare to SOPHiA GENETICS?

Which has stronger valuation and earnings, VRCA or SOPH?

Does the media favor VRCA or SOPH?

Is VRCA or SOPH more profitable?

Do analysts recommend VRCA or SOPH?

Do institutionals and insiders hold more shares of VRCA or SOPH?

Which has more volatility & risk, VRCA or SOPH?

Summary

How does Verrica Pharmaceuticals compare to Larimar Therapeutics?

Does the media refer more to LRMR or VRCA?

Do analysts prefer LRMR or VRCA?

Which has more volatility & risk, LRMR or VRCA?

Do institutionals & insiders have more ownership in LRMR or VRCA?

Is LRMR or VRCA more profitable?

Which has higher valuation & earnings, LRMR or VRCA?

Summary

How does Verrica Pharmaceuticals compare to Compass Therapeutics?

Do analysts recommend VRCA or CMPX?

Which has higher earnings & valuation, VRCA or CMPX?

Does the media refer more to VRCA or CMPX?

Do institutionals and insiders believe in VRCA or CMPX?

Which has more volatility & risk, VRCA or CMPX?

Is VRCA or CMPX more profitable?

Summary

How does Verrica Pharmaceuticals compare to Rocket Pharmaceuticals?

Do insiders and institutionals believe in VRCA or RCKT?

Does the media favor VRCA or RCKT?

Which has more volatility & risk, VRCA or RCKT?

Which has stronger valuation and earnings, VRCA or RCKT?

Is VRCA or RCKT more profitable?

Do analysts prefer VRCA or RCKT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRCA vs. The Competition

Verrica Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools